Clinical Trials Browser

Interventional × Esophageal Neoplasms × Ramucirumab × Clear all

NCT06445972 2026-03-16

MK-3475-06D

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT03008278 2026-02-03

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Phase 1/2 Completed

51 enrolled 20 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT06251973 2025-12-02

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT02970539 2022-02-16

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Phase 1 Unknown

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT01246960 2014-10-08

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Phase 2 Completed

168 enrolled 16 charts

Gastrointestinal

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms